PIK3CA and breast cancer: Therefore, the findings suggest that mutation count could serve as a practical and reliable surrogate marker for PR status prediction in PIK3CA-mutated breast cancer, potentially facilitating more accessible molecular profiling in routine clinical practice without compromising predictive accuracy.